The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | ZUMA-1 trial observations
Speaking from the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago, IL, Paolo Strati, MD, of the University of Texas MD Anderson Cancer Center, Houston, RX, discusses the Phase I ZUMA-1 trial (NCT02348216). There is now the potential for longer follow-up periods and hence further observations on the potential toxicity of the drugs used, so this trial focused on the axi-cell regimen. Although there was good recovery of CD8 and NK cells, there was only minor recovery of B-cells observed despite the target effect of CAR T-cells in CD19 markers.
